Clinical trial

Multigene Risk Score Combined With Ki-67 Dynamic Assessment in Stratified Neoadjuvant Endocrine Therapy Treatment With or Without CDK4/6 Inhibitors in HR+/HER2- Breast Cancer

NCT06650748

Study summary

ClinicalTrials.gov

Multigene Risk Score Combined With Ki-67 Dynamic Assessment in Stratified Neoadjuvant Endocrine Therapy Treatment With or Without CDK4/6 Inhibitors in HR+/HER2- Breast Cancer

Design: INTERVENTIONAL · Status: ENROLLING BY INVITATION · Phase: PHASE2

Loading study purpose, treatment groups and outcomes…

View the complete registry record, eligibility and contacts at ClinicalTrials.gov

Drugs and interventions used in this trial

2 registered

These interventions are listed by ClinicalTrials.gov. An RxNorm link indicates a mapped medicine record; the registry name alone is not proof of a specific branded formulation.

DRUG · Unmapped registry intervention Dalpiciclib Find medicine records · Find other trials using this name

DRUG · Mapped RxNorm record Letrozole Normalized identity: letrozole View linked drug · Find medicine records · Find other trials using this name

StatusENROLLING_BY_INVITATION

Study typeINTERVENTIONAL

Start date2025-05-01

PhasePHASE2

Conditions

Breast Cancerverified · MONDO: breast cancer

Early-stage Breast Cancerunresolved

Interventions

DalpiciclibDRUG

LetrozoleDRUG · verified · RxNorm: letrozole

Sponsors & collaborators

Peking Universitylead sponsor

Mapped research locations

BeijingChina1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT06650748 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.